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ABSTRACT 
 
Remote ischaemic conditioning (RIC) is achieved by repeated transient ischaemia of a 
distant organ/limb and is neuroprotective in experimental ischaemic stroke. However, the 
optimal time and methods of administration are unclear. Systematic review identified 
relevant preclinical studies; two authors independently extracted data on infarct volume, 
neurological deficit, RIC method (administration time, site, cycle number, length of limb 
occlusion (dose)), species and quality. Data were analysed using random effects models; 
results expressed as standardised mean difference (SMD). In 57 publications 
incorporating 99 experiments (1406 rats, 101 mice, 14 monkeys), RIC reduced lesion 
volume in transient (SMD -2.0; 95%CI -2.38, -1.61; p<0.00001) and permanent (SMD -
1.54; 95% CI -2.38, -1.61; p<0.00001) focal models of ischaemia; and improved 
neurological deficit (SMD -1.63; 95%CI -1.97, -1.29, p<0.00001). In meta-regression, 
cycle length and number, dose and limb number did not interact with infarct volume, 
although country and physiological monitoring during anaesthesia did. In all studies, RIC 
was ineffective if the dose was <10 or >50 minutes. Median study quality was 7 (range 
4-9/10); Egger’s test suggested publication bias (p<0.001). RIC is most effective in 
experimental stroke using a dose between 10 and 45 minutes. Further studies using 
repeated dosing in animals with co-morbidities are warranted. 
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INTRODUCTION 
The paradigm of ischaemic conditioning conferring organ protection from a subsequent 
or ongoing ischaemic insult has been under investigation since the 1980s 1 but its 
apparent pre-clinical benefit has yet to be translated consistently in randomised 
controlled trials. The potential to induce ischaemic tolerance in distant tissue beds by 
remote, transient, non-lethal limb ischaemia (remote ischaemic conditioning, RIC) is an 
attractive therapeutic strategy in terms of cost and ease of intervention delivery, 
performed simply by inflating a blood pressure cuff on an arm or leg. 
 
Applying RIC before, during or after an ischaemic event (pre-conditioning [RIPreC], per-
conditioning [RIPerC] or post-conditioning [RIPostC]) shows promise in multiple vascular 
diseases.2-4 However, although early trials of RIC prior to coronary artery bypass grafting 
demonstrated a reduction in peri-operative myocardial injury, larger phase III trials were 
neutral in improving long term outcomes,5, 6 which is potentially explained by interactions 
with cardioprotective anaesthetic agents.7 In the setting of protecting the brain from injury 
with RIC, multiple neuro-humoral mechanism are implicated (see 8), but human clinical 
evidence is limited. In a large meta-analysis of randomised trials of ischaemic 
conditioning in all conditions, the risk of recurrent stroke was significantly reduced, 
though the evidence is of low quality.9 Further, early proof-of-concept human trials 
assessing RIC in acute stroke (RIPerC and RIPostC),3, 10, 11 intracranial stenosis 
(RIPostC) 12, 13 and carotid stenting (RIPreC) have commenced.14 
 
Despite the move into human trials, there are a number of unanswered questions 
regarding the application of RIC, namely optimal method (e.g. one versus two limbs), 
dose (number and length of cycles of limb ischaemia and reperfusion), and timing of 
intervention. We therefore systematically reviewed and meta-analysed the accumulating 
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pre-clinical evidence in acute stroke models of RIPreC, RIPerC and RIPostC to help 
provide further insight and inform future work.  
 
METHODS 
The systematic review was performed in accordance with Preferred Reporting Items for 
Systematic reviews and Meta-Analyses (PRISMA) guidelines.15 The protocol was 
registered with PROSPERO, reference CRD42018095739. Preclinical (non-human) 
studies evaluating the effects of RIC in animal models with induced focal ischaemic 
stroke were searched up to December 2019 in Embase, Medline, Pubmed and Web of 
Science. Two authors independently performed the search and acquired the data. 
Search key words included: (stroke or cerebrovascular disease or brain infarction or 
brain ischemia or carotid artery disease or cerebral artery disease or cerebrovascular 
accident or (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or 
CVA))) AND (remote isch?emic conditioning or (remote adj3 (preconditioning or 
perconditioning or postconditioning)) or RIC or RIPerC or RIPostC or RIP or RIPC or 
RPC or IPerC or rIPC).  
  
The identified abstracts and titles of the studies were checked and removed if they were 
not relevant to the study. If only the abstract of a study was available, it was excluded. 
The studies were included if the following criteria were met: (i) there was a control group; 
(ii) the study was completed in nonhuman subjects; (iii) a focal ischaemic stroke, not 
global; (iv) treatment was given in acute models (within 7 days), not chronic; (v) RIC was 
the only treatment administered, not in conjunction with other treatments; (vi) RIC must 
be administered before, during or after the onset of an ischaemic stroke; (vii) there were 
measures on infarct size or neurological score; (viii) data was from original articles not 
review articles. 
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Risk of selection, performance, detection, attrition and reporting bias was assessed using 
SYRCLE’s risk of bias tool.16 
 
Data Acquisition  
The number of animals, mean outcome, standard deviation or standard error of the mean 
were collected for control and treatment groups. Studies providing summary data on the 
infarct size as a volume or area (mm3 or as a percentage [%] of the whole brain size) and 
neurological score were gathered from all included papers along with species, gender, 
stroke model and quality. If data was not written, published graphs were enlarged and 
the position of the data points determined using Grab software (version 1.10) on Apple 
Mac. If studies conducted more than one experiment against a single control, the number 
of animals in the control group was divided by the number of comparison groups (to 
prevent double counting control animals). Data were independently extracted by three 
authors (PW, RM and TE). 
 
The time of first dose was recorded relative to the time of ischaemia onset and not the 
time of reperfusion. For example, if RIC commenced 10 minutes after reperfusion in a 
transient model of 120 minutes middle cerebral artery occlusion (MCAo), a time of 130 
minutes was recorded.17 Time of treatment was categorised as either RIPreC (treatment 
started before ischaemia), RIPerC (after ischaemia onset but before reperfusion) or 
RIPostC (started after reperfusion). It was not possible to consistently separate RIPerC 
and RIPostC groups and these were combined to form one group.  
 
Study Quality 
The quality of the article from included studies was assessed using the scoring system 
recommended by CAMARADES (range 1-10).18, 19 A point was awarded to the study if it 
met the following criteria: (i) peer-reviewed publication (ii) statement of control of 
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temperature, (iii) random allocation to treatment or control, (iv) blinded induction of 
ischaemia, (v) blinded assessment of outcome, (vi) use of anaesthetic without significant 
intrinsic neuroprotective activity, (vii) appropriate animal model (transient, permanent, 
embolic or photothrombotic models), (viii) sample size calculation, (ix) compliance with 
animal welfare regulation, (x) statement of potential conflicts of interest. Further, 
assessment of data quality was determined by the presence or absence of physiological 
monitoring during anaesthesia, including blood glucose, blood gas, cerebral blood flow 
and blood pressure. 
 
Data Analysis 
The data was analysed using Cochrane Review Manager (version 5.3, Copenhagen, 
The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) according to pre-
specified subgroups: species, model of ischaemia (permanent versus transient), time of 
administration (RIPreC vs RIPerC and RIPostC), dose (number, length and total length 
of cycles) and study quality. Continuous data is presented as a standardised mean 
difference with 95% confidence intervals. Statistical significance was set at p<0.05. 
Egger’s statistic and meta-regression of subgroups was performed using Stata/SE 
(version 15.1 for Mac). Data reliability was assessed through sensitivity analyses by re-
analysing the dose-response relationship in all studies that provided a statement of 
physiological monitoring during anaesthesia. 
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RESULTS 
Study characteristics 
The primary search for studies on Medline, Pubmed, Embase and Web of Science 
identified 804 studies (Supplementary Figure I). After the exclusion criteria were applied, 
57 studies remained and were used in the meta-analysis. Studies were conducted across 
seven countries (Canada [n=1], China [43], Italy [1], Japan [1], Russia [2], Slovak 
Republic [2] and USA [7]) across 41 laboratories. In 99 experimental paradigms including 
1521 animals, RIPreC, RIPerC and RIPostC significantly reduced infarct volume, SMD -
1.87 (95% CI, -2.18, -1.56), which was equivalent to a 34% reduction (weighted by 
number of animals per study) compared to control.  
 
Eighty of the 99 experiments used Sprague-Dawley rats (n=1311 animals), five tested 
Wistar rats (n=50), two examined outbred rats (n=43), eight studied C57BL/6 mice 
(n=89), one studied CD1 mice (n=12) and only three used primates (n=14) 
(Supplementary Table I). The majority of publications (n=81 experiments) induced 
transient focal cerebral ischaemia ranging from 10 to 120 minutes of MCAo. In three 
studies,20-22 ischaemia was induced by embolic MCAo and three studies used permanent 
models of middle cerebral artery  occlusion.23-25 RIC was mostly administered by 
occlusion of the femoral arteries or hind limbs (Supplementary Table I), however, in one 
study RIC was achieved through infrarenal aortic occlusion (categorised as bilateral limb 
occlusion) 26 and another study occluded the unilateral renal artery.27 The administration 
and frequency of RIC varied between studies and therefore allowed a comparison 
between different times of administration and the number and length of cycles. Timing of 
treatment was not clear in two of the experiments, which were consequently excluded 
from time-to-treatment analyses.28, 29 
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All studies 
RIC was significantly effective in both RIPreC and RIPerC/RIPostC models (Table 1, 
Figures I and II), the greatest magnitude in the latter, though there was no interaction 
with infarct volume when the two groups were analysed in meta-regression (SMD [95% 
CI]: RIPreC -1.54 [-2.07, -1.01] versus -2.0 [-2.38, -1.61,], p=0.368). Notably, there was 
significant statistical heterogeneity: I2 = 71% in RIPreC studies and 80% in per/post 
conditioning experiments. Efficacy was evident in both transient and permanent stroke 
models though much fewer animals were assessed with permanent ischaemia (n=140). 
RIC was not effective if the length of each cycle was less than 5 minutes, or if the total 
length of limb ischaemia was less than 10 minutes (Table 1). RIC also improved 
neurological function significantly (SMD -1.63 [-1.97, -1.29], p<0.00001) in studies using 
the Garcia 18-point scale (by 2.5 points, p=0.002), Longa 5-point scale (0.9 points), focal 
neurological score (9.7 points), the 12-point scale (1.4 points) and the Spetzler motor 
score in monkeys (1.5 points); but not in studies using the Neurological Severity Score 
or the 3-point scale (Table 1).  
 
Pre-conditioning (RIPreC) 
We assessed protocol variables against infarct volume change in the RIPreC studies 
using meta-regression. There was a significant interaction caused by species, with RIC 
effective in rats but not mice (p=0.01, Figure 3A). RIC cycle length (up to 15 minutes) 
and total length of limb occlusion (>30 minutes and up to 45 minutes) significantly 
reduced infarct volume, with longer periods of cycle length and total limb ischaemia 
leading to greater falls in infarct volume (although there was no significant interaction 
with meta-regression p=0.115 and 0.102 respectively, Figure 3A). Using either one or 
two limbs to administer RIPreC reduced infarct volume, but using one limb was not 
significantly better than two limbs (SMD -2.00 [-2.76, -1.24] versus -0.72 [-1.29, -0.16], 
p=0.134). 
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Per- and post-conditioning (RIPerC and RIPostC) 
We assessed protocol variables against infarct volume change in the RIPerC and 
RIPostC studies using meta-regression (Figure 3B). Infarct volume was significantly 
decreased in all species except Rhesus monkeys; reduced in transient and permanent 
models; with one, two, three or four cycles of RIC; total length of limb occlusion was 
effective >10minutes but not at 50 minutes; and using one or two limbs. There was no 
interaction with species, model type, cycle number or length, and total length of limb 
occlusion. Using two limbs might be more effective than one (SMD -2.53 [-3.07, -1.99] 
versus -1.33 [-1.78, -0.89]) but the use of four limbs was worse than both meaning there 
was no significant interaction with limb number (p=0.182). 
 
Study quality and risk of bias 
Quality of study median score was 7 (range 4 to 9, Supplementary Table I and II). The 
study quality score did not impact on infarct volume estimate (meta-regression p=0.495, 
Figure 4a). Median risk of bias score was 7 and ranged from 5 to 10 (Supplementary 
Table I and III); the score also did not influence infarct volume (p=0.672). The cohort of 
studies were of reasonable quality with 68% of publications giving statements on 
randomisation and blinded assessment of outcome, but only 6% using a sample size 
calculation and 57% provided a statement on conflicts of interest. Further, statements of 
physiological monitoring during anaesthesia were limited: blood pressure 25%, blood 
gas 19%, blood glucose 5% and regional CBF 40%. Monitoring of blood glucose and 
CBF interacted significantly with the infarct volume outcomes (p=0.047 and p=0.032 
respectively), in that those studies which monitored glucose and CBF demonstrated 
greater reductions in infarct volume (Figure 4b).  
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In sensitivity analyses (dose-response by studies with statements of physiological 
monitoring, n=57 of 99 experiments), an effective dose range remained between 15 and 
45 minutes of total limb occlusion time using two, three or four cycles of RIC 
(Supplementary Figure II). Analysing for further sources of statistical heterogeneity 
determined that there was no interaction by laboratory, but there was by country, with 
greatest efficacy seen in studies from China (Supplementary Figure III). Begg’s funnel 
plot (Figure 5) indicates an asymmetry in published studies, i.e. the possibility of missing 
data due to a publication bias (Egger’s statistic p<0.001).  
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DISCUSSION 
This comprehensive systematic review and meta-analysis of 1521 animals has 
confirmed the potent effect of remote ischaemic conditioning in improving infarct volume 
and neurological outcome in pre-clinical stroke models when applied before the insult 
(RIPreC) or during and after the stroke (RIPerC and RIPostC). In all studies, the average 
reduction in infarct volume in RIC groups compared to control was 34% and appeared 
to be efficacious in RIPerC/RIPostC studies more than RIPreC, in both rats and mice, in 
transient and permanent ischaemia, using one or two limbs and using a total length of 
limb ischaemia > 10 minutes. Total length of limb ischaemia for greater than 50 minutes 
was ineffective with an optimal period between 15 and 45 minutes. 
 
Both RIPreC and RIPerC/RIPostC groups demonstrated significant statistical 
heterogeneity and our pre-specified subgroup analyses in both experimental paradigms 
helped to explore the reasons for this. In RIPreC experiments, there was a significant 
interaction with species, suggesting that RIPreC was ineffective in mice; RIPerC/RIPostC 
was equally effective in rats and mice, however. This raises concern of treatment failure 
when moving into human clinical trials due to inter-species differences. There was only 
one study assessing larger gyrencephalic species, a recent study assessing the effects 
of RIPerC on stroke related cardiac dysfunction in rhesus monkeys (5 control, 9 RIC);22 
multi-limb RIPC improved motor neurological scores (in addition to reducing cardiac 
enzymes, von-Willebrand factor and C-reactive protein) without affecting cerebral infarct 
volume, suggesting improvements might be mediated through improving endothelial 
injury and anti-inflammatory mechanisms. This study is confounded by a small sample 
size and the use of Propofol during anaesthesia, which interferes with RIC efficacy and 
a factor that may have contributed to the neutral findings in prior cardiac bypass surgery 
RIC trials.7 Clinical trials assessing RIC in mechanical thrombectomy in hyperacute 
stroke (often using general anaesthesia) need to factor this into their design. Other trials 
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of RIC in cerebrovascular disease are underway and small trials have been completed.30 
Interpreting results will, however, be challenging since they are fraught with 
heterogeneity in terms of RIC protocols and stroke subtype assessed. 
 
RIPreC studies showed no significant interaction with the total length of limb occlusion 
(a product of cycle number and length of each cycle, reflecting the ‘dose’ of RIC), though 
only doses greater than 25 minutes reduced infarct volume significantly. Doses above 
45 minutes were not tested in the RIPreC group but were ineffective in the 
RIPerC/RIPostC group suggesting the presence of a therapeutic window. A higher dose 
may also be reflected by the number of limbs used to administer RIC, but here we 
obtained no statistical interaction with the number of limbs used in either of the 
subgroups. We did not find any differences in the number of cycles used nor in the length 
per cycle, though analysis of all studies revealed the therapeutic window of total dose to 
be between 15 and 45 minutes. Whether repeated dosing provides additional benefit 
remains largely untested except in two studies, where RIPostC for up to 14 days was 
more effective at improving outcome than a single per-conditioning dose.31, 32 
Interestingly, delayed daily RIPostC, started at day five, using three cycles of 10 minutes 
of limb ischaemia, improved neurological function and brain injury (without impacting on 
early lesion volume) through pleiotropic effects such as angioneurogenesis and 
modulation of the inflammatory response.32  
 
The mechanisms of RIC are still under exploration, appear to be multi-modal, and not 
fully dependent on achieving reperfusion, which is important since only 50% of strokes 
achieve early recanalization after iv thrombolysis.33 Beneficial mechanisms, in addition 
to attenuation of reperfusion injury, include anti-inflammatory,34 anti-oedema,35, 36 
angioneurogenic,31, 32, 37 anti-platelet,38 and vasodilatory (enhancement of collateral 
microvascular circulation) effects,39 mediated through numerous neurohumoral chemical 
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messengers,8 including release from endothelial derived exosomes.40 This meta-
analysis confirms that RIC reduces infarct volume in both transient ischaemic models 
(standardized mean difference, SMD 1.93, p<0.0001) and permanent models (SMD 
1.59, p<0.001), suggesting that reperfusion is not necessary, though desirable, for RIC 
to achieve beneficial effects. 
 
The majority of papers is this review utilise young male rodents with a notable absence 
of animals with co-morbidities such as age, hypertension and diabetes, factors which 
may inhibit the effects of RIC.41 Of some concern is the absence of effect seen in an 
aged model of right MCAO occlusion treated with ‘direct’ ischaemic conditioning (not 
remote).42 Studies are present testing RIC efficacy in female rodents (n=46) 40, 43, 44 which 
is important to examine considering the neuroprotective effects and potential interaction 
of female hormones.45 In post-hoc analyses, RIC studies in female rodents reduce infarct 
volume to a similar extent to that seen in all studies (SMD -1.76 95% CI -3.07 to -0.45, 
p=0.009, excluding Xiao 2017 which contains both male and female rats). Other 
experimental paradigms important for translation into human trials have also been tested 
including co-administration of thrombolysis (a synergistic effect),43, 46, use in large 
animals,22 experiments specifically designed to address dose response 47 and the time-
window of administration. 32  
 
The risk of bias in our findings exists considering the presence of significant statistical 
heterogeneity. This does not appear to be explained by differences in study quality 
(CAMARADES criteria) or risk of bias (SYRCLE criteria).48 Indeed, reporting of 
randomisation and blinding of outcome assessments were moderately high (68%) but, 
disappointingly, the use of sample size calculations (6%) is lacking despite calls to 
include these in animal study design.49 Sources of heterogeneity were significant for the 
presence/absence of physiological monitoring of CBF and glucose, and also the country 
 
 14 
in which the experiment was performed (but not the laboratory). Somewhat reassuringly, 
in sensitivity analyses, an effective RIC dose range between 15 and 45 minutes 
remained. The presence of significant publication bias also raises concern, theoretically 
leading to an under- or over-estimation of effects due to unpublished neutral or negative 
data. It is also feasible that we missed publications in our literature search but this was 
comprehensively performed independently by two authors. Overall, however, this is a 
robust and comprehensive review of the current literature strengthened by pre-
registration and pre-specified analyses. 
 
In summary, RIC significantly reduces lesion volume and neurological impairment in 
experimental models of focal ischaemic stroke. Statistical heterogeneity may be 
explained by RIPreC cycle length, dose and number of limbs; monitoring CBF and 
glucose during anaesthesia; and country in which the experiment was conducted. Dose 
analyses suggests a therapeutic window of between 10 and 45 minutes in RIPerC and 
RIPostC models. The presence of publication bias raises the possibility that 
neutral/negative studies have been performed but not published. Pre-clinical studies in 
animals with co-morbidities using protocols with repeated dosing that would be deemed 
feasible in humans are warranted. 
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Table 1:   The effect of administration time, species, stroke model, and RIC administration method on (A) 
infarct volume in all preclinical studies of remote ischaemic pre- per- and post-conditioning, compared to 
control; and (B) the effect of remote ischaemic pre- per- and post-conditioning, compared to control, on 
neurological score. P-values compare the RIC group to control. 
 No. of 
experimen
ts 
No. of 
animals 
SMD [95% CI] P-value 
A. Lesion Volume 
Time of Administration     
Remote Ischaemic Pre-Conditioning 27 361 -1.54 [-2.07, -1.01] <0.00001 
Remote Ischaemic Per/Post-Conditioning 72 1160 -2.00 [-2.38, -1.61] <0.00001 
Species     
Sprague-Dawley Rats 80 1313 -2.13 [-2.50, -1.77] <0.00001 
Wistar Rats  5 50 -1.02 [-1.88, -0.16] 0.02 
Outbred Rats  2 43 -0.36 [-1.15, 0.43] 0.38 
C57BL/6 Mice 8 89 -1.07 [-1.82, -0.32] 0.005 
CD1 Mice 1 12 -4.11 [-6.41, -1.81] 0.0005 
Rhesus Monkey 3 14 0.16 [-0.97, 1.30] 0.78 
Stroke Model     
Permanent ischaemia 13 140 -1.59 [-2.34, -0.84] <0.0001 
Transient ischaemia - All 81 1339 -1.97 [-2.32, -1.63] <0.00001 
30 minute ischaemic model 4 49 -2.93 [-4.75, -1.11] 0.002 
45 minute ischaemic model 4 30 -0.03 [-0.97, 0.90] 0.95 
60 minute ischaemic model 7 109 -1.12 [-1.81, -0.43] 0.0003 
90 minute ischaemic model 31 505 -2.67 [-3.36, -1.99] <0.00001 
100 minute ischaemic model 11 105 -1.02 [-1.72, -0.32] 0.005 
120 minute ischaemic model 24 541 -1.98 [-2.53, -1.44] <0.00001 
Number of RIC cycles     
1 cycle 10 95 -1.29 [1.94, -0.63] 0.0001 
2 cycles 8 71 -1.20 [-2.02, -0.37] 0.005 
3 cycles 62 1114 -2.33 [-2.75, -1.91] <0.00001 
4 cycles 11 159 -1.20 [-1.94, -0.45] 0.002 
More than 4 cycles 3 40 -0.51 [-1.10, 0.08] 0.09 
Length of each RIC cycle     
< 5 min cycles 2 18 -1.81 [-4.07, 0.44] 0.11 
5 min cycles 29 403 -1.32 [-1.82, -0.83] <0.00001 
10 min cycles 36 777 -2.36 [-2.90, -1.82] <0.00001 
15 min cycles  22 234 -1.64 [-2.22, -1.05] <0.00001 
> 15 min cycles 4 37 -2.40 [3.74, 1.07] 0.0004 
Total length of limb ischaemia     
Less than 1 min 2 18 -1.81 [-4.07, 0.44] 0.11 
5 mins 2 20 -0.52 [-1.43, 0.39] 0.27 
10 mins 5 47 -0.84 [-1.49, -0.20] 0.01 
15 mins 16 220 -2.17 [-3.07, -1.27] <0.00001 
20-25 mins 16 205 -1.07 [-1.64, -0.50] 0.0003 
30 mins 32 731 -2.39 [-2.96, -1.82] <0.00001 
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40-45 mins 18 208 -2.06 [-2.73, -1.38] <0.00001 
50 mins + 2 20 -0.07 [-0.81, 0.68] 0.86 
Number of limbs occluded     
One 40 485 -1.53 [-1.92, -1.14] <0.00001 
Two 54 994 -2.15 [-2.60, -1.69] <0.00001 
B. Neurological Score 
Method*     
Garcia 18-point scale 8 200 -2.52 [-4.10, -0.94] 0.002 
Longa 5-point scale 27 406 -0.89 [-1.09, -0.69] <0.00001 
Focal neurological score 1 30 -9.70 [-10.57, -8.83] <0.00001 
Neurological severity score 5 194 -3.03 [-6.43, 0.38] 0.08 
3-point scale 3 30 -0.36 [-0.76, 0.04] 0.08 
12-point scale 10 163 -1.37 [-2.26, -0.47] 0.003 
Spetzler motor score 3 14 -1.48 [-2.03, -0.92] <0.00001 
RIC, remote ischemic conditioning; SMD, standardised mean difference; *Neurological score data expressed as weighted mean difference 
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Figure Legends 
Figure 1. Effect of remote ischemic pre-conditioning (RIPreC) compared to control on 
infarct volume, expressed as a standardised mean difference, by individual publication 
experiment 
Figure 2. Effect of remote ischemic per- and post-conditioning (RIPerC and RIPostC) 
compared to control on infarct volume, expressed as a standardised mean difference, by 
individual publication experiment 
Figure 3. Subgroup analyses of RIC in experimental stroke. Each point estimate 
represents the change in infarct volume in treated animals compared to control, divided by 
subgroups according to animal model and RIC administration (pre-conditioning, RIPreC; 
per-& post-conditioning, RIPerC & RIPostC). The p values, obtained through meta-
regression analyses, indicate whether the respective parameter has a significant 
interaction with infarct volume. 
Figure 4. Impact of study quality on infarct volume by (a) CAMARADES criteria: each 
point represents one study, the size of the circle is proportional to the study size. The y-
axis is infarct volume change expressed as the standardised mean difference (SMD) 
between RIC treated animals and control. The was no statistical interaction with study 
quality and infarct volume (meta regression p=0.495); and (b) measurement of 
physiological monitoring (blood glucose, blood gas, cerebral blood flow (CBF), and blood 
pressure (BP)). The p values indicate whether the respective parameter has a significant 
interaction with infarct volume. 
Figure 5. Begg’s funnel plot. An asymmetric funnel indicates a relationship between 
treatment effect estimate and study precision. Egger’s test suggested significant 
publication bias (p<0.001). 
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Figure 1. Effect of remote ischemic pre-conditioning compared to control 
on infarct volume, expressed as a standardised mean difference, by 
individual publication experiment
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-1.21 (-2.44, 0.01)
0.03 (-0.88, 0.94)
-0.17 (-1.41, 1.07)
-2.28 (-4.41, -0.16)
-1.68 (-3.28, -0.09)
-1.01 (-2.66, 0.64)
-0.93 (-2.27, 0.42)
-5.70 (-9.78, -1.62)
-1.23 (-2.52, 0.05)
-0.89 (-2.60, 0.82)
-5.54 (-7.04, -4.03)
-6.27 (-10.12, -2.41)
-3.12 (-5.27, -0.97)
-4.11 (-6.41, -1.81)
-0.63 (-1.92, 0.66)
-0.85 (-2.99, 1.30)
-0.62 (-2.23, 1.00)
-0.82 (-2.43, 0.80)
-1.79 (-2.27, -1.32)
0.27 (-0.98, 1.52)
-0.39 (-1.65, 0.87)
-7.47 (-11.95, -2.99)
100.00
0.97
1.27
0.72
1.51
0.44
1.60
1.84
1.53
1.01
1.59
1.53
1.08
0.49
1.43
1.64
1.63
1.36
1.47
1.48
1.40
1.91
1.89
1.49
1.42
1.78
1.66
1.68
1.69
1.11
1.55
1.27
1.66
0.90
1.37
0.95
1.91
Weight
1.19
1.47
1.19
1.13
0.71
1.11
1.78
1.73
1.21
1.16
1.51
1.58
1.57
1.56
1.67
1.81
1.66
1.24
1.49
1.46
1.61
0.61
1.64
1.43
1.53
0.66
1.23
1.16
1.64
1.23
1.48
1.48
1.95
1.66
1.65
0.53
%
  
0-20.5 20.5
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Figure 3 
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Supplementary Table I  
 
Study  Species  Model 
(mins) 
Number and 
length of cycles  
Method of RIC  Time of administration Measurement and units Time of 
assessment  
Quality 
of 
study 
score 
Risk of 
bias 
score  
Bonova 201450          
Experiment 1 & 
2 
M, albino 
Wistar rats  
T 90  3 cycles, 5 min 
phases 
Hind limbs 1 h pre-; 0.5 h post-
ischaemia 
Infarct size -mm3 24 h 7 5 
Experiments 3 & 
4 
    0.5 h post-ischaemia Longa 5-point scale 24 h   
Burda 201451 M & F, albino 
Wistar rats 
T 10 1 cycle, 20 min 
phases 
Hind limbs  48 h post-ischaemia  Morris water maze test - 
seconds 
Day 6 & 7 7 6 
Chen 201452          
Experiment 1 M Sprague-
Dawley rats 
T 120 3 cycles, 15 min 
phases 
Femoral artery At reperfusion Infarct size - % 24 h 7 8 
Experiment 2      Postural reflex test    
Experiment 3       Vibrissae-elicited forelimb 
placing test - % 
   
Experiment 4      Tail hang test - %    
Chen 201653          
Experiment 1 M Sprague-
Dawley rats 
T 90 3 cycles, 5 min 
phases 
Femoral artery  At reperfusion Infarct size - % 24 h 7 8 
Experiments 2-4     0; 1 h; 3 h post-
reperfusion  
Postural reflex test    
Experiments 5-7     0; 1 h; 3 h post-
reperfusion 
Tail hang test - %    
Chen 2016a36          
Experiment 1 M Sprague-
Dawley rats 
T 90 3 cycles, 15 min 
phases 
Femoral artery  Immediately pre-
ischaemia 
Infarct size - % 48 h 7 6 
Experiment 2      Longa 5-point scale 48 h   
Chen 201854          
Experiment 1 M Sprague-
Dawley rats 
T 120 3 cycles, 15 min 
phases 
Hind limb Immediately pre-
reperfusion 
Infarct size - % 24 h  8 7 
Experiment 2      Longa 5-point scale 24 h   
Cheng 201455 M Sprague-
Dawley rats 
T 90 3 cycles, 5 min 
phases  
Hind limb Immediately post-
ischaemia 
Infarct size - % 24 h 6 6 
Cheng 201856 M C57BL/6 
mice 
T 60 3 cycles, 10 min 
phases 
Bilateral femoral 
arteries  
Immediately post-
ischaemia  
Infarct size - % 3 days 9 9 
Gao 201757          
Experiments 1-3 M Sprague-
Dawley rats 
T 120 3 cycles, 10 min 
phases 
Bilateral femoral 
arteries  
0; 10; 30 mins post-
reperfusion 
Infarct size - % 24 h 7 8 
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Experiment 4-6     0; 10; 30 mins post-
reperfusion 
Garcia 18-point scale 24 h   
 
 
Guo 201858 
         
Experiment 1 M C57BL/6 
mice 
T 120 3 cycles, 10 min 
phases 
Bilateral femoral 
arteries  
At reperfusion Infarct size - % 12 h 8 9 
Experiment 2      Longa 5-point scale 12 h   
Guo 201922 
Experiments 1-3 
Male Rhesus 
Monkeys 
Thrombo
-embolic 
10 cycles, 5 min 
phases  
1, 2,or 4 limbs Immediately post-
ischaemia 
Infarct size – mm3 
 
Spetzler rating scale 
24 hours  
 
3h 1d 30d 
60d 
7
  
5 
Hahn 201159          
Experiment 1 & 
2 
M Sprague-
Dawley rats 
T 120 4 cycles, 5 min 
phases 
Hind limb 40 mins pre-; 80 mins 
post-ischaemia 
Infarct size -mm3 24 h 4 5 
Hoda 201220          
Experiment 1 M C57BL/6 
mice 
P 5 cycles, 5 min 
phases 
Hind limb 120 mins post-ischaemia  Infarct size - % 48 h 7 10 
Experiment 2      Longa 5-point scale 48 h   
Hoda 201421          
Experiment 1 F C57BL/6 
mice  
P 4 cycles, 10 min 
phases 
Hind limb 120 mins post-ischaemia Infarct size - % 24 h 8 10 
Experiment 2      Longa 5-point scale 24 h   
Hu 201260          
Experiment 1 M Sprague-
Dawley rats 
T 120 3 cycles, 5 min 
phases 
Hind limb 60 mins pre-ischaemia Infarct size – mm3 24 h 7 8 
Experiment 2      Longa 5-point scale 24 h   
Hu 201361          
Experiment 1-5 M Sprague-
Dawley rats 
T 60 3 cycles, 5 min 
phases 
Hind limb  60 mins pre-ischaemia Morris water maze test - 
seconds 
3, 4, 5, 6 and 
7 days 
8 8 
Huang 201762          
Experiment 1 M Sprague-
Dawley rats 
T 90 3 cycles, 10 min 
phases 
Bilateral femoral 
arteries  
90 mins post-ischaemia Infarct size - % 3 days 7 8 
Experiment 2-8      Neurological severity 
score 18-point scale 
1, 2, 3, 7, 14, 
21 and 28 
days 
  
Jin 201663 M Sprague-
Dawley rats 
T 30 3 cycles, 15 min 
phases  
Femoral artery  60 mins pre-ischaemia Infarct size - % 24 h 7 6 
Kitagawa 
201864 
         
Experiments 1-4 M C57BL/6 
mice  
T 45 
mins 
4 cycles, 5 min 
phases  
Hind limbs  24 h pre-; immediately 
pre-; immediately post- 
ischaemia; at reperfusion 
Infarct size -mm3 24 h 5 7 
Experiments 5-8     24 h pre-; immediately 
pre-; immediately post- 
ischaemia; at reperfusion 
Longa 5-point scale 24 h   
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Kong 201365          
Experiment 1 M Sprague-
Dawley rats 
T 120 3 cycles, 5 min 
phases 
Femoral artery  At reperfusion Infarct size - % 48 h 5 6 
Experiments 2-4     At reperfusion  Neurological severity 
score 18-point scale 
24 h, 48 h 
and 7 days 
  
Liang 201866 M Sprague-
Dawley rats 
T 90 3 cycles, 10 min 
phases 
Hind limbs 2 days post-ischaemia 
and continued for 21 
days 
Infarct size – mm3 21 days 6 7 
Li 201567          
Experiment 1 M CD1 mice T 60 3 cycles, 5 min 
phases 
Bilateral femoral 
arteries 
Immediately post-
ischaemia 
Infarct size - % 24 h 7 8 
Experiment 2      Focal neurological score 
28-point scale 
   
Li 2015a44 M Sprague-
Dawley rats  
T 120  3 cycles, 10 min 
phases 
Bilateral femoral 
arteries 
Immediately post-
ischaemia 
Longa 5-point scale 24 h  7 8 
Li 201668          
Experiments 1 & 
2 
F Sprague-
Dawley rats 
T 60 3 cycles, 10 min 
phases 
Bilateral femoral 
arteries 
Immediately post-
ischaemia 
Infarct size - % 1 and 3 days 8 9 
Experiments 3 & 
4 
     Garcia 18-point scale 1 and 3 days   
Liu 201469          
Experiment 1 M Sprague-
Dawley rats 
T 120 3 cycles, 10 min 
phases 
Bilateral femoral 
arteries 
At reperfusion Infarct size - % 24 h 8 8 
Experiment 2      12-point scale    
Liu 2014a70           
Experiments 1 & 
2 
M Sprague-
Dawley rats 
T 120 3 cycles, 10 min 
phases 
Bilateral femoral 
arteries  
8; 24 h post-ischaemia Infarct size - % 8 h and 24 h 6 6 
Experiments 3 & 
4 
    8; 24 h post-ischaemia Longa 5-point scale    
Liu 201671          
Experiment 1 M Sprague-
Dawley rats 
T 90 4 cycles, 5 min 
phases 
Bilateral femoral 
arteries 
60 mins pre-ischaemia Infarct size – mm3 3 days 9 8 
Experiments 2-5      Longa 5-point scale 0.5, 24, 48 
and 72 h 
  
Liu 201828 M Sprague-
Dawley rats 
T 30 3 cycles, 15 min 
phases 
Femoral artery  Post-ischaemia Infarct size - % 48 h 6 5 
Liu 201972 M Sprague-
Dawley rats 
T 120 3 cycles, 10 min 
phases 
Bilateral femoral 
arteries 
1 hr pre-ischaemic Infarct size 
Neurological severity 
score 18-point scale 
7 days 
1, 3, 7 days 
4 3 
Ma 201373          
Experiment 1 M Sprague-
Dawley rats 
T 90 3 cycles, 10 min 
phases 
Bilateral femoral 
arteries 
Immediately post-
ischaemia 
Infarct size - % 24 h 5 6 
Experiment 2     Immediately post-
ischaemia 
12-point scale    
Malhorta 201126          
Experiments 1-3 M Wistar rats T 120 3 cycles, 10 min 
phases 
Infrared aortic 
occlusion 
24; 48; 72 h pre-
ischaemia 
Infarct size – mm3 24 h  5 8 
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Experiments 4-6     24; 48; 72 h pre-
ischaemia 
3-point scale    
Pignataro 
201374 
         
Experiments 1, 
4, 5, 6 & 8 
M Sprague-
Dawley rats 
T 100 10 cycles, 10 min 
phases; 1 cycle, 10 
and 20 min phases; 
2 cycles, 10 min 
phases; 1 cycle, 10 
min rep & 20 min 
occ 
Femoral artery 10 mins post-reperfusion Infarct size - % 24 h 6 7 
Experiments 2, 
3 & 7 
  2, 3 or 1 cycles, 5 
min phases 
 5 mins post-reperfusion      
Experiment 9-11   1 cycle, 20, 30 or 40 
min rep, 20 min occ 
 20, 30 or 40 mins post-
reperfusion 
    
Qi 201275          
Experiments 1-3 M Sprague-
Dawley rats 
T 120 3, 4 or 5 cycles, 10 
min phases 
Bilateral femoral 
arteries 
0; 10; 30 mins post-
reperfusion 
Infarct size - % 22 h 6 7 
Experiments 4-6   3, 4 or 5 cycles, 10 
min phases 
 0; 10; 30 mins post-
reperfusion 
12-point scale    
Ren 200823          
Experiments 1-3 M Sprague-
Dawley rats 
P 2 cycles, 5 min 
phases; 2 or 3 
cycles, 15 min 
phases 
Femoral artery  Immediately pre-
ischaemia 
Infarct size - % 24 h 7 6 
Experiments 4 & 
5 
  2 or 3 cycles, 15 
min phases 
 12 h pre-ischaemia     
Experiment 6    3 cycles, 15 min 
phases 
 2 days pre-ischaemia     
Ren 200924          
Experiments 1-3 M Sprague-
Dawley rats 
P 3 cycles, 15 min 
phases 
Femoral artery  Immediately; 3 h; 6 h 
post-ischaemia 
Infarct size - % 2 days 4 9 
Experiment 4     Immediately post-
ischaemia 
 60 days   
Experiments 5-
11 
    Immediately post-
ischaemia  
Vibrissae-elicited forelimb 
placing test - % 
2, 7, 14, 21, 
30, 37, 60 
days 
  
Ren 201176 M Sprague-
Dawley rats 
T 90 3 cycles, 10 min 
phases 
Bilateral femoral 
arteries 
Immediately post-
ischaemia 
Infarct size - % 24 h  6 5 
Ren 201531          
Experiments 1 & 
2 
M Sprague-
Dawley rats 
T 90 3 cycles, 10 min 
phases 
Bilateral femoral 
arteries  
Immediately post- 
ischaemia; immediately 
post- ischaemia for 14 
days 
Infarct size - % 7 and 14 
days 
7 7 
Experiments 3, 
4 and 6 
    Immediately post- 
ischaemia 
12-point scale  1, 7 and 14 
days 
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Experiments 5 & 
7 
    Immediately post- 
ischaemia for 14 days 
12-point scale 7 and 14 
days 
  
Experiments 8, 
9 & 11 
    Immediately post-
ischaemia  
Tail hang test - % 1, 7 and 14 
days 
  
Experiment 10 & 
12 
    Immediately post-
ischaemia for 14 days 
Tail hang test - % 7 and 14 
days 
  
 
 
Ren 2015a77 
         
Experiment 1 M Sprague-
Dawley rats 
T 90 3 cycles, 10 min 
phases  
Hind limbs  Immediately post-
ischaemia 
Infarct size - % 48 h 7 7 
Experiments 2 & 
3 
     12-point scale 2 and 48 h   
Ren 201837 Male Sprague-
Dawley rats 
T 90 3 cycles, 10 mins 
phases 
Hind limbs  Immediately post-
ischaemia and continued 
for 14 days 
Tail hang test - % 
Foot fault 
14 days 9 7 
Shan 201378 Male Sprague-
Dawley rats 
T 90 3 cycles, 5 min 
phases 
Hind limbs 60 mins post-ischaemia Infarct size - % 24 h  5 8 
Silachev 201227 M outbred 
white rats 
T 60 3 cycles, 5 min 
phases 
Unilateral renal 
arteries  
24 h pre-ischaemia Infarct size - % 24 h 6 5 
Silachev 201779 M outbred 
white rats  
T 60 3 cycles, 5 min 
phases 
Hind limbs 24 h pre-ischaemia Infarct size – mm3 24 h  8 6 
Su 201480          
Experiment 1 M Sprague-
Dawley rats 
T 120 4 cycles, 10 min 
phases 
Bilateral femoral 
arteries 
10 mins post-reperfusion  Infarct size - % 24 h  7 8 
Experiments 2-5      Garcia 18-point scale 1, 2, 3 and 7 
days 
  
Sun 201247          
Experiments 1-3 M Sprague-
Dawley rats 
T 90 3 cycles, 15 
seconds, 5 or 8 min 
phases 
Bilateral femoral 
arteries  
3 h post-ischaemia Infarct size - % 72 h  7 7 
Experiments 4-6   3 cycles, 15 
seconds, 5 or 8 min 
phases 
 6 h post-ischaemia     
Wang 201181          
Experiment 1 M Sprague-
Dawley rats 
T 120 3 cycles, 10 min 
phases 
Femoral artery  At reperfusion Infarct size - % 24 h  6 8 
Experiment 2      Garcia 18-point scale    
Wei 201282        8 8 
Experiment 1  M Sprague-
Dawley rats 
T 30 3 cycles, 15 min 
phases 
Femoral artery  Immediately pre-
ischaemia  
Infarct size - % 48 h    
Experiments 2-5      Postural reflect test 1, 2, 7 and 
44 days 
  
Experiment 6-13      Vibrissae-elicited forelimb 
placing test - % 
1, 2, 7, 10, 
14, 21, 44 
and 60 days 
  
Xia 201783          
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Experiment 1 M Sprague-
Dawley rats 
T 90 4 cycles, 5 min 
phases  
Hind limbs  60 mins pre-ischaemia  Infarct size - % 24 h 7 7 
Experiment 2       Neurological severity 
score 18-point scale  
24 h    
Xiao 201584          
Experiment 1  M Sprague-
Dawley rats  
T 30  3 cycles, 10 min 
phases 
Bilateral femoral 
arteries 
Immediately post-
ischaemia  
Infarct size - % 24 h 7 8 
Experiment 2       12-point scale 24 h   
Xiao 201740 M & F 
Sprague-
Dawley rats 
T 120 3 cycles, unclear 
length  
Femoral artery  2 h post-ischaemia Infarct size – mm3 24 h  4 6 
Xu 201285          
Experiments 1-3 M Sprague-
Dawley rats  
T 90 1, 2 or 3 cycles, 15 
min phases  
Bilateral femoral 
arteries  
At reperfusion  Infarct size - % 24 h  6 9 
Experiment 4-6   1, 2 or 3 cycles, 10 
min phases 
  Infarct size - %    
Experiments 7-9   1, 2 or 3 cycles, 5 
min phases 
  Infarct size - %     
Experiments 10-
12 
  1, 2 or 3 cycles, 15 
min phases  
  Longa 5-point scale    
Experiments 13-
15 
  1, 2 or 3 cycles, 10 
min phases 
  Longa 5-point scale    
Experiments 16-
18 
  1, 2 or 3 cycles, 5 
min phases  
  Longa 5-point scale    
Xu 201725          
Experiment 1 M Sprague-
Dawley rats 
P 3 cycles, 15 min 
phases 
Femoral artery  Immediately pre-
ischaemia  
Infarct size - %  48 h 7 8 
Experiment 2 & 
3 
     Vibrissae-elicited forelimb 
placing test - % 
24 and 48 h    
Yang 201886          
Experiment 1 Sprague-
Dawley rats  
T 90 3 cycles, 10 min 
phases 
Hind limbs 24 hours pre-ischaemia Infarct size - % 24 hours 8 9 
Experiment 2      Longa 5-point scale 24 hours   
Experiment 3      Postural reflex test  24 hours    
Experiment 4      Tail hang test - % 24 hours   
Zhang 201287          
Experiment 1 M Sprague-
Dawley rats 
T 120 3 cycles, 10 min 
phases 
Bilateral femoral 
arteries  
Daily for 3 days pre-
ischaemia 
Infarct size - % 24 h  6 6 
Experiment 2       12-point scale    
Zhang 201788          
Experiment 1 M Sprague-
Dawley rats 
T 120 3 cycles, 10 min 
phases 
Bilateral femoral 
arteries  
At reperfusion  Infarct size - % 24 h  6 7 
Experiment 2      Garcia 18-point scale    
Zhao 201989 M Sprague-
Dawley rats 
T 120 4 cycles, 5 min 
phases  
Bilateral femoral 
arteries 
24 hours pre-ischaemia Infarct size - % 
Neurological severity 
score 18-point scale 
24 h 5 5 
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Zhou 201590          
Experiment 1 M Sprague-
Dawley rats 
T 90 3 cycles, 10 min 
phases 
Bilateral femoral 
arteries 
At reperfusion Infarct size - % 24 h 5 6 
Experiment 2      Longa 5-point scale    
Zong 201591          
Experiment 1 Sprague-
Dawley rats 
T 60 3 cycles, 10 min 
phases 
Hind limbs Post-ischaemia  Infarct size - % 3 days  8 9 
Experiment 2-4      Garcia 18-point scale 1, 3 and 7 
days 
  
T, transient ischaemia; P, permanent ischaemia; F, female; M, male; occ, occlusion; rep, reperfusion.  
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Supplementary Table II 
Assessment of quality in all studies 
 
 
 
Compliance 
with animal
Statement of 
potential
welfare 
regulation 
conflicts of 
interest 
Bonova 2015 1 1 0 0 1 1 1 0 1 1 7
Burda 2014 1 1 1 0 1 1 1 0 1 0 7
Chen 2014 0 1 1 0 1 1 1 0 1 1 7
Chen 2016 1 0 1 0 1 1 1 0 1 1 7
Chen 2016a 1 1 1 0 0 1 1 0 1 1 7
Chen 2018 1 1 1 0 1 1 1 0 1 1 8
Cheng 2014 1 1 1 0 0 1 1 0 1 0 6
Cheng 2018 1 1 1 1 1 1 1 0 1 1 9
Gao 2017 1 1 1 0 1 1 1 0 1 0 7
Guo 2018 1 1 1 0 1 1 1 0 1 1 8
Guo 2019 1 0 0 1 1 1 1 0 1 1 7
Hahn 2011 1 0 1 0 0 1 1 0 0 0 4
Hoda 2012 1 0 1 0 1 1 1 1 1 0 7
Hoda 2014 1 0 1 0 1 1 1 1 1 1 8
Hu 2012 1 1 1 0 1 1 1 0 1 0 7
Hu 2013 1 1 1 0 1 1 1 0 1 1 8
Huang 2017 1 1 1 0 1 1 1 0 1 0 7
Jin 2016 1 1 1 0 0 1 1 0 1 1 7
Kitagawa 2018 1 0 0 0 1 1 1 0 1 0 5
Kong 2013 1 0 1 0 0 1 1 0 1 0 5
Liang 2018 1 1 0 0 1 1 1 0 1 0 6
Li 2015 0 1 1 0 1 1 1 0 1 1 7
Li 2015a 1 0 1 0 1 1 1 0 1 1 7
Li 2015b 1 1 1 0 1 1 1 0 1 1 8
Liu 2014 1 1 1 0 1 1 1 0 1 1 8
Liu 2014a 1 1 1 0 0 1 1 0 1 0 6
Liu 2016 1 1 1 0 1 1 1 1 1 1 9
Liu 2017 1 1 1 0 0 1 1 0 1 0 6
Liu 2019 0 1 0 0 0 1 1 0 0 1 4
Ma 2013 0 1 1 0 0 1 1 0 0 1 5
Malhorta 2011 1 1 1 0 1 1 1 0 1 0 7
Pignataro 2013 1 0 0 0 1 1 1 0 1 0 5
Qi 2012 1 0 0 0 1 1 1 0 1 1 6
Ren 2008 1 1 1 0 0 1 1 0 1 0 6
Ren 2009 1 1 1 0 1 1 1 0 1 0 7
Ren 2011 0 1 0 0 0 1 1 0 1 0 4
Ren 2015 0 1 0 0 1 1 1 0 1 1 6
Ren 2015a 1 1 0 0 1 1 1 0 1 1 7
Ren 2018 1 1 0 0 1 1 1 0 1 1 7
Shan 2013 1 1 1 1 1 1 1 0 1 1 9
Silachev 2012 1 1 0 0 0 1 1 0 1 0 5
Silachev 2017 1 1 1 0 0 1 1 0 1 0 6
Su 2014 1 1 1 0 1 1 1 0 1 1 8
Sun 2012 1 1 0 0 1 1 1 0 1 1 7
Wang 2011 0 1 1 0 1 1 1 0 1 0 6
Wei 2012 1 1 1 0 1 1 1 0 1 1 8
Xia 2017 1 1 0 0 1 1 1 0 1 1 7
Xiao 2015 1 0 1 0 1 1 1 0 1 1 7
Xiao 2017 0 1 0 0 0 1 1 0 1 0 4
Xu 2012 0 1 1 0 1 1 1 0 1 0 6
Xu 2017 1 1 1 0 1 1 1 0 1 0 7
Yang 2018 1 1 1 0 1 1 1 0 1 1 8
Zhang 2013 1 1 0 0 0 1 1 0 1 1 6
Zhang 2017 1 0 0 0 1 1 1 0 1 1 6
Zhao 2019 1 1 0 0 0 1 1 0 0 1 5
Zhou 2015 0 1 1 0 0 1 1 0 0 1 5
Zong 2015 1 1 1 0 1 1 1 0 1 1 8
Sample size 
calculation 
Overall ScoreStudy
Peer-reviewed 
publication 
Blinded 
induction of 
ischaemia 
Blinded 
assessment of 
outcome 
Use of 
neuroprotectiv
e anaesthetic 
Appropriate 
animal model
Statement of 
control of 
temperature
Random 
allocation
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Supplementary Table III 
SYRCLE assessment of bias in all studies 
 
 
 
  
Study Selection Bias 
Performance 
Bias 
Detection Bias Attrition Bias Reporting Bias Other Overall Score
Sequence 
generation 
Baseline 
characteristics
Allocation 
concealment 
Random 
housing
Blinding
Random 
outcome 
assessment 
Blinding 
Incomplete 
outcome data 
Selective 
outcome 
reporting
Other sources 
of bias 
Bonova 2015 1 0 0 0 1 0 0 1 1 1 5
Burda 2014 0 1 0 0 1 1 1 1 1 0 6
Chen 2014 1 1 0 0 1 1 1 1 1 1 8
Chen 2016 1 1 0 0 1 1 1 1 1 1 8
Chen 2016a 1 1 0 0 0 1 0 1 1 1 6
Chen 2018 1 1 0 0 1 1 0 1 1 1 7
Cheng 2014 1 1 0 0 0 1 0 1 1 1 6
Cheng 2018 1 1 0 1 1 1 1 1 1 1 9
Gao 2017 1 1 0 0 1 1 1 1 1 1 8
Guo 2018 1 1 1 0 1 1 1 1 1 1 9
Guo 2019 0 0 0 0 1 0 1 1 1 1 5
Hahn 2011 1 0 0 0 1 1 0 1 1 0 5
Hoda 2012 1 1 1 1 1 1 1 1 1 1 10
Hoda 2014 1 1 1 1 1 1 1 1 1 1 10
Hu 2012 1 1 0 0 1 1 1 1 1 1 8
Hu 2013 1 1 0 0 1 1 1 1 1 1 8
Huang 2017 1 1 0 0 1 1 1 1 1 1 8
Jin 2016 1 1 0 0 0 1 0 1 1 1 6
Kitagawa 2018 1 1 0 0 1 0 1 1 1 1 7
Kong 2013 1 1 0 0 0 1 0 1 1 1 6
Liang 2018 1 1 0 0 1 0 1 1 1 1 7
Li 2015 1 1 0 0 1 1 1 1 1 1 8
Li 2015a 1 1 0 0 1 1 1 1 1 1 8
Li 2015b 1 1 1 0 1 1 1 1 1 1 9
Liu 2014 1 1 0 0 1 1 1 1 1 1 8
Liu 2014a 1 1 0 0 0 1 0 1 1 1 6
Liu 2016 1 1 0 0 1 1 1 1 1 1 8
Liu 2017 1 1 0 0 0 0 0 1 1 1 5
Liu 2019 0 0 0 0 0 1 0 1 1 0 3
Ma 2013 1 1 0 0 0 1 0 1 1 1 6
Malhorta 2011 1 1 0 0 1 1 1 1 1 1 8
Pignataro 2013 1 1 0 0 1 0 1 1 1 1 7
Qi 2012 1 1 0 0 1 0 1 1 1 1 7
Ren 2008 1 1 0 0 0 1 0 1 1 1 6
Ren 2009 1 1 1 0 1 1 1 1 1 1 9
Ren 2011 1 1 0 0 0 0 0 1 1 1 5
Ren 2015 1 1 0 0 1 0 1 1 1 1 7
Ren 2015a 1 1 0 0 1 0 1 1 1 1 7
Ren 2018 1 1 0 0 1 0 1 1 1 1 7
Shan 2013 1 1 0 0 1 1 1 1 1 1 8
Silachev 2012 1 1 0 0 0 0 0 1 1 1 5
Silachev 2017 1 1 0 0 0 1 0 1 1 1 6
Su 2014 1 1 0 0 1 1 1 1 1 1 8
Sun 2012 1 1 0 0 1 0 1 1 1 1 7
Wang 2011 1 1 0 0 1 1 1 1 1 1 8
Wei 2012 1 1 0 0 1 1 1 1 1 1 8
Xia 2017 1 1 0 0 1 0 1 1 1 1 7
Xiao 2015 1 1 0 0 1 1 1 1 1 1 8
Xiao 2017 1 1 1 0 0 0 0 1 1 1 6
Xu 2012 1 1 0 1 1 1 1 1 1 1 9
Xu 2017 1 1 0 0 1 1 1 1 1 1 8
Yang 2018 1 1 0 1 1 1 1 1 1 1 9
Zhang 2013 1 1 0 1 0 0 0 1 1 1 6
Zhang 2017 1 1 0 0 1 0 1 1 1 1 7
Zhou 2015 1 1 0 0 0 1 0 1 1 1 6
Zhao 2019 0 0 0 0 1 0 1 1 1 1 5
Zong 2015 1 1 0 1 1 1 1 1 1 1 9
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Supplementary Figure I  
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Supplementary Figure II  
Subgroup analyses of RIC in experimental stroke by studies reporting measurement of 
physiology during anesthesia. Each point estimate represents the change in infarct volume 
in treated animals compared to control, divided by subgroups according to animal model 
and RIC administration. The p values indicate whether the respective parameter has a 
significant interaction with infarct volume (meta-regression analyses). 
 
 
 
 
 
 
-4 -2 0 2
Four limbs
Two limbs
One Limb
>50 mins
40-45 mins
30 mins
20-25 mins
15 mins
10 mins
5 mins
<1 min
>15 mins
15 mins
10 mins
5 mins
<5 mins
>4 cycles
4 cycles
3 cycles
2 cycles
1 cycle
Infarct volume
(Standardised Mean Difference)
Sensitivity analysis: studies reporting physiological monitoring only
Cycle length
Number of cycles
Number of limbs
Total length of limb 
occlusion
p=0.142
p=0.633
p=0.143
p=0.215
 
 42 
  
 
 43 
Supplementary Figure III 
Subgroup analyses of RIC in experimental stroke by country. Each point estimate 
represents the change in infarct volume in treated animals compared to control, divided by 
groups according to animal model and RIC administration ((a) all studies; (b) RIPreC; (c) 
RIPerC & RIPostC). The p-values indicate a significant interaction by country with infarct 
volume (meta-regression, p=0.002). 
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